Cargando…
Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019
BACKGROUND: Guidelines for the management of dyslipidemias recommend intensive low-density lipoprotein (LDL-C) control through lifestyle advice and lipid-lowering drugs to reduce the risk of cardiovascular disease (CVD). OBJECTIVE: This retrospective study aimed to characterize the adult primary car...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994561/ https://www.ncbi.nlm.nih.gov/pubmed/35411162 http://dx.doi.org/10.2147/CEOR.S347085 |
_version_ | 1784684131522707456 |
---|---|
author | Bilitou, Aikaterini Were, John Farrer, Archie Rabe, Adrian Ming, Simon Wan Yau Haq, Inaam Dunton, Kyle |
author_facet | Bilitou, Aikaterini Were, John Farrer, Archie Rabe, Adrian Ming, Simon Wan Yau Haq, Inaam Dunton, Kyle |
author_sort | Bilitou, Aikaterini |
collection | PubMed |
description | BACKGROUND: Guidelines for the management of dyslipidemias recommend intensive low-density lipoprotein (LDL-C) control through lifestyle advice and lipid-lowering drugs to reduce the risk of cardiovascular disease (CVD). OBJECTIVE: This retrospective study aimed to characterize the adult primary care population with primary hypercholesterolemia (PH)/mixed dyslipidemia (MD). METHODS: Data on adults with PH/MD between 1 January 2009 and 31 December 2019 in the UK were extracted from linked primary Clinical Practice Research Datalink (CPRD) and secondary care (Hospital Episode Statistics) datasets and analyzed. RESULTS: A total of 279,221 patients met the inclusion criteria. Mean follow-up was 8.6 years. Crude prevalence of PH/MD increased from 13.5% in 2009 to 23.5% by 2019. The incidence decreased from 176 to 49 per 100,000 population. Mean age of the cohort was 58 years, baseline LDL-C was 4.32 mmol/L, 19.6% had atherosclerotic CVD, 30.1% diabetes, and 8.5% heterozygous familial hypercholesterolemia. Estimated LDL-C reductions of 40% and 50% were achieved in 2.6% and 2.3% of patients, respectively. Most received moderate-intensity statins as monotherapy (62.4%); high-intensity statins were used less frequently (24.3% as initial treatment). Less than 10% of patients received ezetimibe plus statins of different intensities. CONCLUSION: The prevalence of dyslipidemia doubled between 2009 and 2019, likely due to more systematic identification of PH/MD. A large proportion of patients with PH/MD are of high and very high CV risk, remain suboptimally treated in terms of lipid lowering, and may experience CV events with associated non-negligible clinical and economic sequelae. Despite intensive LDL-C-lowering recommendations, these do not translate in clinical practice to the wider population. |
format | Online Article Text |
id | pubmed-8994561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-89945612022-04-10 Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 Bilitou, Aikaterini Were, John Farrer, Archie Rabe, Adrian Ming, Simon Wan Yau Haq, Inaam Dunton, Kyle Clinicoecon Outcomes Res Original Research BACKGROUND: Guidelines for the management of dyslipidemias recommend intensive low-density lipoprotein (LDL-C) control through lifestyle advice and lipid-lowering drugs to reduce the risk of cardiovascular disease (CVD). OBJECTIVE: This retrospective study aimed to characterize the adult primary care population with primary hypercholesterolemia (PH)/mixed dyslipidemia (MD). METHODS: Data on adults with PH/MD between 1 January 2009 and 31 December 2019 in the UK were extracted from linked primary Clinical Practice Research Datalink (CPRD) and secondary care (Hospital Episode Statistics) datasets and analyzed. RESULTS: A total of 279,221 patients met the inclusion criteria. Mean follow-up was 8.6 years. Crude prevalence of PH/MD increased from 13.5% in 2009 to 23.5% by 2019. The incidence decreased from 176 to 49 per 100,000 population. Mean age of the cohort was 58 years, baseline LDL-C was 4.32 mmol/L, 19.6% had atherosclerotic CVD, 30.1% diabetes, and 8.5% heterozygous familial hypercholesterolemia. Estimated LDL-C reductions of 40% and 50% were achieved in 2.6% and 2.3% of patients, respectively. Most received moderate-intensity statins as monotherapy (62.4%); high-intensity statins were used less frequently (24.3% as initial treatment). Less than 10% of patients received ezetimibe plus statins of different intensities. CONCLUSION: The prevalence of dyslipidemia doubled between 2009 and 2019, likely due to more systematic identification of PH/MD. A large proportion of patients with PH/MD are of high and very high CV risk, remain suboptimally treated in terms of lipid lowering, and may experience CV events with associated non-negligible clinical and economic sequelae. Despite intensive LDL-C-lowering recommendations, these do not translate in clinical practice to the wider population. Dove 2022-04-05 /pmc/articles/PMC8994561/ /pubmed/35411162 http://dx.doi.org/10.2147/CEOR.S347085 Text en © 2022 Bilitou et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Bilitou, Aikaterini Were, John Farrer, Archie Rabe, Adrian Ming, Simon Wan Yau Haq, Inaam Dunton, Kyle Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
title | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
title_full | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
title_fullStr | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
title_full_unstemmed | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
title_short | Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019 |
title_sort | prevalence and patient outcomes of adult primary hypercholesterolemia and dyslipidemia in the uk: longitudinal retrospective study using a primary care dataset from 2009 to 2019 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994561/ https://www.ncbi.nlm.nih.gov/pubmed/35411162 http://dx.doi.org/10.2147/CEOR.S347085 |
work_keys_str_mv | AT bilitouaikaterini prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT werejohn prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT farrerarchie prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT rabeadrian prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT mingsimonwanyau prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT haqinaam prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 AT duntonkyle prevalenceandpatientoutcomesofadultprimaryhypercholesterolemiaanddyslipidemiaintheuklongitudinalretrospectivestudyusingaprimarycaredatasetfrom2009to2019 |